Hospital-based Dermatopathology. Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM
|
|
- Caitlin Chambers
- 5 years ago
- Views:
Transcription
1 Hospital-based Dermatopathology Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM
2 Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy (another lecture)
3 There are some remedies worse than the disease. Publilius Syrus (c. 42 BC)
4 Drug eruptions Cutaneous reactions to drug are the most common adverse reaction to drugs Most common cause of skin biopsies in hospital setting 2% of all hospital consultations Approximately 2% are considered serious Predisposing factors: age, female gender, and immunosuppression
5 Historical data Boston Collaborative Drug Surveillance Program ,247 inpatients with 565 drug-related skin eruptions (2.5%) Outpatient estimates also from 1-3%
6 Classic Drug eruptions Exanthematous/maculopapular/morbilliform (46%) Urticarial (23%) Fixed drug (10%) EM/SJS/TEN (5%) Other (16%)
7 Histopathologic features Recognized histologically and drug etiology assigned:
8 Histopathologic features Recognized histologically and drug etiology assigned: fixed drug eruption
9 Histopathologic features Recognized histologically and drug etiology assigned: fixed drug eruption Recognizable histologic pattern, causative role of drug not always apparent:
10 Histopathologic features Recognized histologically and drug etiology assigned: fixed drug eruption Recognizable histologic pattern, causative role of drug not always apparent: urticaria
11 Histopathologic features Recognized histologically and drug etiology assigned: fixed drug eruption Recognizable histologic pattern, causative role of drug not always apparent: urticaria Histology is non-specific :
12 Histopathologic features Recognized histologically and drug etiology assigned: fixed drug eruption Recognizable histologic pattern: causative role of drug not always apparent: urticaria Histology is non-specific : morbilliform
13 Morbilliform (exanthematous) drug eruptions Most common eruptions produce non-specific findings Up to 50% of drug eruptions List of over 100 medications causing it Amoxicillin, ampicillin, miconazole, and streptomycin in >5% of patients receiving drug Proposed to be immunologically-mediated reactions Clinically, very difficult to differentiate from viralinduced morbilliform eruptions
14
15
16
17 Histology in ~100 clinically morbilliform drug eruptions Gerson, et al. JAAD 2008
18 Morbilliform Drug Eruptions 82% of cases had inflammatory cells in superficial dermis 80% cases had perivascular and interstitial pattern 50% cases had eosinophils 50% cases had the focal vacuolar interface changes
19 Urticarial Drug Eruptions
20
21
22
23
24
25
26 Fixed drug eruption Not a common cause of biopsy Face and male genitalia are most common sites Ampicillin, barbiturates, NSAIDs Resolves with residual hyperpigmentation
27
28 Acute Generalized Exanthematous Pustulosis (AGEP) Within 10 days of starting drug High fevers and malaise Generalized toxic erythema studded with non-small non-follicular pustules Cephalosporins, Bactrim, furosemide, hydroxychloroquine
29
30
31
32
33 Pustular Psoriasis
34 DRESS syndrome Drug reaction with eosinophilia and systemic symptoms (DRESS) has an estimated mortality of 10% Most frequent skin finding: morbilliform rash Systemic involvement includes hematologic, hepatic, renal, pulmonary, cardiac, neurologic GI and endocrine abnormalities Currently no universally recognized diagnostic criteria
35 Etiology Many agents, but carbamazepine is most frequent 2-6 weeks after drug administration Associations include: Drug detoxification enzyme abnormalities Possible reactivation of herpes viruses Certain HLA alleles
36
37
38 Toxic Epidermal Necrolysis Mortality rate is 25-30% Can resemble nonspecific drug reactions characterized by morbilliform eruption Spreads symmetrically from face and trunk to extremities Skin and mucosal eruptions are irregular size and shape and are painful Clinical findings such as %BSA involvement are key
39 Histologic features EARLY LATE
40 Newer classes of drugs Selective BRAF inhibitors α-tnf in rheumatic diseases Acneiform eruptions with EGFR-inhibitors GM-CSF and G-CSF Novel checkpoint blockade agents
41 RAF activation of the MAPK/ERK pathway Gibney GT, et al. Nat Rev Clin Oncol, 2013
42 BRAF inhibitors Squamous lesions, ranging from verrucous keratoses to invasive SCC +/- KA-like features (24/47) 51% of patients developed 146 total cutaneous neoplasms Secondary melanomas have also been reported Other malignancies include RAS-mutant leukemia and colon cancer 1 Sufficool KE, et al J Cutan Pathol 2014
43 Selective BRAF inhibitors Activating BRAF mutations in up to 60% of melanomas BRAF inhibitors have been associated with SCC New melanocytic lesions have also been reported
44
45
46
47 Management of lesions in this setting: 1) Combination therapies with BRAF and MEK inhibitors 2) Use of retinoids, topical 5-FU 3) Frequent skin checks 4) Complete resection of lesions, when possible
48 α-tnf in rheumatic diseases ¼ of patients experience cutaneous side effects Psoriasis and eczema-like (>1/2) Viral, bacterial, an fungal infections (1/3 cases) Other: Dermatitis herpetiformis Lichenoid reactions Leukocytoclastic vasculitis Alopecia Pathogenesis: unopposed IFN-alpha by plamacytoid dendritic cells in genetically predisposed
49
50 Doyle, et al. Am J Dermpath, 2011
51 EGFR inhibitors Used to treat NSCLC, metastatic CRC, pancreatic cancer, advanced HNSCC EGFR is found on undifferentiated keratinocytes in the epidermis, follicular keratinocytes and sebocytes of the pilosebaceous unit, and cells in outer root sheath of hair follicle Cutaneous reactions in 90% of patients
52 EGFR inhibitors Brodell, et al. J Cutan Pathol, 2013
53
54 GM-CSF and G-CSF
55
56 Novel Immunotherapeutic Agents Signal 2 Two signal model to develop an antigenspecific T-cell response Multiple Accelerators and Brakes Signal 1 Pardoll D, 2012 Pardoll 2012 De novo vs. ongoing response in the periphery Tumors may co-opt checkpoint signals to turn off the host immune response
57 Checkpoint Blockade of CTLA-4 or PD-1 Signaling Ribas A. NEJM 2012
58 Comparison of immune-mediated related dermatitis following checkpoint blockade CTLA-4 blockade PD-1 blockade Phan GQ, et al. PNAS 2008 Blistering dermatitis Taube JM, et al. unpublished data Mild eczematous dermatitis 58
59 Complete regression of metastatic melanoma (anti- PD-1, 3 mg/kg) associated with vitiligo Pre Normal skin Boundary Post Vitiligo History: 62-year-old male had previously developed PD following IL-2, temozolomide, and multiple surgeries.
60 Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy (another lecture)
61 Erythroderma Otherwise healthy adult = drug-based Drug-associated erythroderma Curr Probl Dermatol 2002;14:
62
63
64 Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy (another lecture)
65 Cutaneous Manifestations of Renal Disease Calciphylaxis Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy
66 Frequently lethal Most commonly, but not always ESRD Deep stellate ulcerations with eschar formation Intimal hyperplasia and medial calcification of small dermal and subcutaneous arterioles and arteries Calciphylaxis
67
68 Adjacent areas of a wedge biopsy: Calciphylaxis SubQ Throm Vasc
69 Nephrogenic Systemic Fibrosis Progressive, symmetric hardening of skin over extremities woody induration Acute or chronic renal disease with close relationship to gadolinium exposure
70
71
72
73 Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy (another lecture)
74 Paraneoplastic pemphigus Most often associated with CLL, NHL, Castleman s disease involves stratified squamous epithelium and columnar epithelium of lungs, resulting in progressive bronchiolitis obliterans Variable presentation: some PV-like and many with T-cell mediated disease phenotype, e.g. EM
75
76 Paraneoplastic Pemphigus in absence of detectable antibodies Patients treated with Retuximab Lack autoantibodies detected by DIF, IIF, or immunoprecipitation Lack features of acantholysis on H&E Indicates that PNP may be mediated by cytotoxic T- cells rather than autoantibodies
77 Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy (another lecture)
78 Retiform purpura related to levamisole Chung C., et al. JAAD, 2011
79
80
Emergency Dermatology Dr Melissa Barkham
Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationCutaneous Conditions Associated with Systemic Disease
Cutaneous Conditions Associated with Systemic Disease Johnnie M Woodson, M.D., F.A.A.D. Assistant Professor of Dermatology University of Nevada School of Medicine Director of J. Woodson Dermatology & Associates,
More informationSignificance. Outline and Objectives. S007 Systemic Therapies for Medical Oncology
S007 Systemic Therapies for Medical Oncology Anisha B. Patel, M.D. Assistant Professor, Dermatology UT MD Anderson Cancer Center UT Health Science Center Houston Safety considerations Outline and Objectives
More informationCUTANEOUS DRUG REACTIONS OR I WOULDN T HAVE SEEN IT, IF I HADN T BELIEVED IT Edmund J. Rosser Jr., DVM, DACVD
CUTANEOUS DRUG REACTIONS OR I WOULDN T HAVE SEEN IT, IF I HADN T BELIEVED IT Edmund J. Rosser Jr., DVM, DACVD DERMATOLOGY Pathogenesis Immunologic: can involve Type I, II, III, IV hypersensitivity reactions.
More informationSkin Manifestations of Drug Reactions
Skin Manifestations of Drug Reactions Dr Carol Hlela, Division of Dermatology Department of Medicine, University of Cape Town and Red Cross Children s Hospital What are the Skin Manifestations of Drug
More informationREGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More information=ﻰﻤاﻤﺤﻠا ﺔﻴﻘﻠﺤﻠا ﺔذﺒاﻨﻠا
1 / 15 Erythema Annulare Centrifugum and Other Figurate Erythemas The figurate erythemas include a variety of eruptions characterized by annular and polycyclic lesions. Classification of this group has
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationTHE INTEGUMENTARY SYSTEM. Body Membranes & Skin
THE INTEGUMENTARY SYSTEM Body Membranes & Skin TYPES OF MEMBRANES Epithelial Membranes includes layer of epithelial cells and connective tissue Serous Cutaneous Mucous Connective Tissue Membranes solely
More informationUndergraduate Dermatology Curriculum July 2016
Undergraduate Dermatology Curriculum July 2016 British Association of Dermatologists Introduction This document is the 2016 revised dermatology undergraduate curriculum (UK) from the British Association
More informationParadoxial Safety Signals from Biologics
Paradoxial Safety Signals from Biologics Christopher Ritchlin, MD, MPH Professor of Medicine Director, Translational Immunology Research Center University of Rochester Medical Center Rochester, NY Disclosures
More informationInpatient dermatopathology. Inpatient dermatopathology. Inpatient dermatopathology: Histologic patterns that matter most
Inpatient dermatopathology: Histologic patterns that matter most Beth S. Ruben, M.D. Associate Clinical Professor University of California, San Francisco Departments of Dermatology and Pathology Dermatopathology
More informationDERMATOLOGIC EMERGENCIES. Mary Evers D.O., F.A.O.C.D. Georgetown, Texas
DERMATOLOGIC EMERGENCIES Mary Evers D.O., F.A.O.C.D. Georgetown, Texas SKIN EMERGENCIES??? Subclassifications: Autoimmune (Anaphylaxis, Vasculitis, Pemphigus) Erythroderma (AGEP, DRESS, SJS, TEN) Infectious
More informationThe Role of Plasmacytoid Dendritic Cells in Psoriasis
6 ème Journée du Groupe de Recherche sur le Psoriasis Paris, 9 novembre 2012 The Role of Plasmacytoid Dendritic Cells in Psoriasis Dr Curdin Conrad, PD & MER Department of Dermatology Psoriasis: Clinical
More informationDepartment of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo , Japan 2
Dermatology Research and Practice Volume 2010, Article ID 931340, 5 pages doi:10.1155/2010/931340 Case Report Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More informationCutanous Manifestation of Lupus Erythematosus. Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university
Cutanous Manifestation of Lupus Erythematosus Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university A 50-year old lady, who is otherwise healthy, presented to the dermatology clinic with
More informationBSD Self Assessment Workshop 7 th July 2013 CASE 27 RAC6123
BSD Self Assessment Workshop 7 th July 2013 CASE 27 RAC6123 M55. 4/7 tender lesions on knee, legs and arms. Also iritis/ weight loss/headache, synovitis.?vasculitis. Sarcoidosis. Biopsy from left elbow
More informationWR SKIN. DERMATOLOGY
WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics
More informationPHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions
PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions 1 Autoimmune Disorders Auto-reactivity: low physiological levels (e.g. tolerance) vs. pathogenic levels 80+ types of autoimmune diseases affect
More informationDrug Allergy A Guide to Diagnosis and Management
Drug Allergy A Guide to Diagnosis and Management (Version 1 April 2015 updated April 2018) Author: Jed Hewitt Chief Pharmacist, Governance & Professional Practice Date of Preparation: April 2015 Updated:
More informationCutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center
Cutaneous Adverse Drug Reactions in Domestic Animals Katherine Doerr, DVM, Dip. ACVD Veterinary Dermatology Center Maitland, Rockledge, Waterford Lakes, FL Not highly studied in veterinary medicine Unknown
More informationSkin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationHerbal and homeopathic products, often considered natural and non-toxic, can also cause adverse drug reactions.
Idiosyncratic and potentially serious cutaneous adverse drug reactions (CADRs), although relatively rare, account for significant morbidity and mortality. RANNAKOE J LEHLOENYA, BSc, MB ChB, FCDerm (SA)
More information9/9/17. Disclosures" Dermatology in Primary Care: Recognition and treatment of common disorders of the skin" A preview" Classic skin infections"
Disclosures Dermatology in Primary Care: Recognition and treatment of common disorders of the skin I have no conflicts of interest to disclose. I may discuss off-label use of treatments for cutaneous disease.
More informationChapter 6 Squamous Cell Carcinoma: Variants and Challenges
Chapter 6 Squamous Cell Carcinoma: Variants and Challenges Michael B. Morgan EPIDEMIOLOGY: Second most common skin cancer, rare in the dark-skinned races. ETIOLOGY: Ultraviolet light, HPV infection. PATHOGENESIS:
More informationPathology of the skin. Dr Fónyad László, 1sz. Patológiai és Kísérleti Rákkutató Intézet, SE
Pathology of the skin Dr Fónyad László, 1sz. Patológiai és Kísérleti Rákkutató Intézet, SE The skin Biggest organ Kb. 1.8 nm Kb. 10 kg Most frequent site for tumor development (BCC) Pathology of the skin
More informationDiploma Examination. Dermatopathology: First paper. Tuesday 20 March Candidates must answer FOUR questions. Time allowed: 3 hours
Dermatopathology: First paper Tuesday 20 March 2018 Candidates must answer FOUR questions Time allowed: 3 hours 1. Give an account of the genetic aberrations encountered in Spitzoid neoplasms and how these
More informationMy Method for Approaching Skin Biopsies
My Method for Approaching Skin Biopsies P A U L H A U N, MD, MS, F A A D A S S I S T A N T P R O F E S S O R D E R M A T O L O G Y A N D D E R M A T O P A T H O L O G Y D E P A R T M E N T O F D E R M
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationSkin Deep Into Toxicities of Cancer Therapies. Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY
Skin Deep Into Toxicities of Cancer Therapies Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY Targeting the Immune System in Cancer. Sharma et al, Nat Rev
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationCutaneous Drug Reactions
Cutaneous Drug Reactions Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses
More informationA. Erythema multiforme and related diseases
Go Back to the Top To Order, Visit the Purchasing Page for Details Chapter Erythema, Erythroderma (Exfoliative Dermatitis) Erythema is caused by telangiectasia or hyperemia in the papillary and reticular
More informationAUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE
AUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE Ron Feldman, MD, PhD Assistant Professor of Dermatology Emory University ron.j.feldman@emory.edu Disclosures I have no conflict of interest to
More informationTargeted Therapies 5/21/2018. Iatrogenic Dermatopathology: When Therapy Goes Wrong
Iatrogenic Dermatopathology: When Therapy Goes Wrong Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu I do not have any relevant relationships with industry Targeted
More information44 year-old male. Follicular Hyperkeratosis 3/4/2019. Clinical: Erythematous scaling papules symmetrically on the forearms, abdomen and lower back
DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Dermatopathology Case Challenge: Recognizing Mimics and Masqueraders Tammie Ferringer, MD Section Head and Fellowship Director of Dermatopathology Depts of Dermatology
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationFive things not to miss in Dermatology. Dr Judy Wismer Associate Clinical Professor Michael G DeGroote School of Medicine
Five things not to miss in Dermatology Dr Judy Wismer Associate Clinical Professor Michael G DeGroote School of Medicine Key Descriptives Fever, skin pain Purpura, necrosis Bullae, Mucosal, Skin sloughing
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationDiagnosis? 2/17/2018. Case year old female. F045 Dermpath Case Challenge
Case 1 75 year old female F045 Dermpath Case Challenge Tammie Ferringer, MD Depts of Dermatology and Pathology Danville, PA tferringer@geisinger.edu 1 year history of undiagnosed joint pain and 6 month
More informationPrincipi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile Grand rounds. Lorenzo Cerroni, Graz
Principi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile 2018 Grand rounds Lorenzo Cerroni, Graz "Computer palms" Described in patient using computer keyboards for long periods; similar features described
More informationUnit 4 - The Skin and Body Membranes 1
Unit 4 - The Skin and Body Membranes 1 I. Unit 4: Skin and Body Membranes A. Body Membranes 1. Function of body membranes a) Cover body surfaces b) Line body cavities c) Form protective sheets around organs
More informationChallenging Cases in Dermatopathology. Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania
Challenging Cases in Dermatopathology Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Rosalie Elenitsas
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationVITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY
VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY VIT D RECEPTORS ROLE IN MAINTAINING NORMAL FOLLICULAR
More informationOncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza
Oncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza Dermatologic adverse events of oncologic drugs Grading of Dermatologic Adverse Events (ver 5.0) 5 grades: mild, moderate,
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationSkin and Body Membranes
4 Skin and Body Membranes PowerPoint Lecture Slide Presentation by Jerry L. Cook, Sam Houston University ESSENTIALS OF HUMAN ANATOMY & PHYSIOLOGY EIGHTH EDITION ELAINE N. MARIEB Skin and Body Membranes
More informationSkin and Body Membranes Body Membranes Function of body membranes Cover body surfaces Line body cavities Form protective sheets around organs
Skin and Body Membranes Body Membranes Function of body membranes Cover body surfaces Line body cavities Form protective sheets around organs Classification of Body Membranes Epithelial membranes Cutaneous
More informationDermatologists & Oncologists: Two important reasons we are getting closer. Ioanna Panoutsopoulou, MD. GAMC June 1 st 2016
Dermatologists & Oncologists: Two important reasons we are getting closer Ioanna Panoutsopoulou, MD GAMC June 1 st 2016 Points of presentation Cutaneous adverse events from: Epidermal Growth Factor Receptor
More informationCh. 4: Skin and Body Membranes
Ch. 4: Skin and Body Membranes I. Body Membranes A. Function of body membranes 1. Cover body surfaces 2. Line body cavities 3. Form protective sheets around organs II. Classification of Body Membranes
More informationDERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE
DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON
More informationConflicts. Objectives. University of Texas Health Science Center at San Antonio. Pediatrics Grand Rounds 24 August Pediatric Dermatology 101
Pediatric Dermatology 101 John C. Browning, MD, FAAD, FAAP Conflicts Investigator: ViroXis Advisor: ViroXis Advisory Board: TopMD Speaker: Galderma Objectives Understand the meaning and importance of cutaneous
More informationPowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College Skin and Body Membranes
PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College Skin and Body Membranes 4 Body Membranes Function of body membranes Cover body surfaces Line body cavities
More informationTHERE IS A GROUP OF PAtients. Defining Urticarial Dermatitis. A Subset of Dermal Hypersensitivity Reaction Pattern
STUDY Defining Urticarial Dermatitis A Subset of Dermal Hypersensitivity Reaction Pattern Steven Kossard, FACD; Ian Hamann, FACD; Barbara Wilkinson, BSc Background: Urticarial dermatitis may represent
More informationMucinoses Diverse group of disorders which have in common deposition of basophilic, finely granular and stringy material in the connective tissues of
Cutaneous Mucinoses Nathan C. Walk, M.D. Mucinoses Diverse group of disorders which have in common deposition of basophilic, finely granular and stringy material in the connective tissues of the dermis.
More informationPrinciples of Anatomy and Physiology
Principles of Anatomy and Physiology 14 th Edition CHAPTER 5 The Integumentary System Introduction The organs of the integumentary system include the skin and its accessory structures including hair, nails,
More informationInflammatory skin disease I Jade Wititsuwannakul, MD Chulalongkorn University, Thailand
Inflammatory skin disease I Jade Wititsuwannakul, MD Chulalongkorn University, Thailand Superficial Perivascular Dermatitis Interface Dermatitis Vacuolar Dermatitis Lichenoid Dermatitis Barnhill Textbook
More informationMelanoma: Early Detection and Therapeutic Progress
Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:
More informationHistopathology: skin pathology
Histopathology: skin pathology These presentations are to help you identify, and to test yourself on identifying, basic histopathological features. They do not contain the additional factual information
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationAdverse Cutaneous Drug Reactions to Cardiovascular Drugs
Adverse Cutaneous Drug Reactions to Cardiovascular Drugs Esen Özkaya Kurtuluş Didem Yazganoğlu 123 Adverse Cutaneous Drug Reactions to Cardiovascular Drugs Esen Özkaya Kurtuluş Didem Yazganoğlu Adverse
More informationPrevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital
International Journal of Research in Dermatology Janardhan B et al. Int J Res Dermatol. 2017 Mar;3(1):74-78 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20164248
More informationStudy. Skin changes in internal malignancy
Study Skin changes in internal malignancy R. Rajagopal, P. N. Arora $, C. V. Ramasastry*, P. K. Kar # Dept of Dermatology, 5 Air Force Hospital, C/o 99 APO, $ Former Prof & Head, Dept. of Dermatology,
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationAn Evidenced-Based Approach to the Adult with a Morbilliform Eruption
Relatively An Evidenced-Based Approach to the Adult with a Morbilliform Eruption Ben Kaffenberger, MD Assistant Professor, Dermatology Director, Inpatient Dermatology Consult Service Ohio State University
More informationCase No. 5; Slide No. B13/8956/2
Interface diseases Case No. 5; Slide No. B13/8956/2 Histological findings Severe hydropic vacuolation of epidermal and follicular basal cells/ interface dermatitis Multifocally apoptotic keratinocytes
More informationOverview of Immunotherapy Related Adverse Event (irae) Management
Overview of Immunotherapy Related Adverse Event (irae) Management DR. ROLAND LEUNG MEDICAL ONCOLOGY DEPARTMENT OF MEDICINE THE UNIVERSITY OF HONG KONG QUEEN MARY HOSPITAL Outline Immune system overview
More informationParaneoplastic Pemphigus in A Patient with Chronic Lymphocytic Leukemia: A Case Report
Case Report Paraneoplastic Pemphigus in A Patient with Chronic Lymphocytic Leukemia: A Case Report Arif Kuş 1, Abdulkerim Yıldız 2*, Betül Erdem 3, Murat Albayrak 2, Çiğdem Pala Öztürk 2, Müzeyyen Gönül
More informationالمركب النموذج--- سبيتز وحمة = Type Spitz's Nevus, Compound SPITZ NEVUS 1 / 7
SPITZ NEVUS 1 / 7 Epidemiology An annual incidence rate of 1.4 cases of Spitz nevus per 100,000 individuals has been estimated in Australia, compared with 25.4 per 100,000 individuals for cutaneous melanoma
More informationWhat are the functions of the integumentary system? What are some disorders of the integumentary system?
Essential Questions: What are the functions of the integumentary system? What are some disorders of the integumentary system? How are integumentary system disorders treated? How do you relate the integumentary
More informationHEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT
HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT Nirmala Ponnuthurai, Sabeera Begum, Lee Bang Rom Paediatric Dermatology Unit, Institute of Paediatric, Hospital Kuala Lumpur, Malaysia Abstract
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationOncologist-induced Disease of the GI tract: New Developments
Oncologist-induced Disease of the GI tract: New Developments Jeffrey D Goldsmith, MD Children s Hospital Boston, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, MA Everyone s on drugs
More informationDiploma examination. Dermatopathology: First paper. Tuesday 21 March Candidates must answer FOUR questions ONLY. Time allowed: Three hours
Dermatopathology: First paper Tuesday 21 March 2017 1. Discuss the role of fluorescent in-situ hybridization (FISH) and emerging molecular techniques in the diagnosis of cutaneous melanocytic lesions,
More informationVARICELLA. Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara
VARICELLA (Chicken pox) Infectious and Tropical Pediatric Division, Department of Child Health, Medical Faculty, University of Sumatera Utara Definition : Varicella is a common contagious disease caused
More informationIntroduction. Results. Discussion. Histopathologic and immunohistochemical findings. Results. conclusions,
1/5 2/5 Carcinoma distinctive carcinoma. form erysipeloides (CE), metastasis. which clinically Itfrom has resembles been termed erysipelas, is an uncommon, but may extend It164 toclassically back, presents
More informationBig rashes in little patients:
! Big rashes in little patients: Severe drug eruptions and cutaneous infections!! Marcia Hogeling, MD, FAAD Assistant Clinical Professor Director, Pediatric Dermatology Division of Dermatology David Geffen
More informationIntroduction. Skin and Body Membranes. Cutaneous Membranes Skin 9/14/2017. Classification of Body Membranes. Classification of Body Membranes
Introduction Skin and Body Membranes Body membranes Cover surfaces Line body cavities Form protective and lubricating sheets around organs Classified in 5 categories Epithelial membranes 3 types- cutaneous,
More informationAn Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
An Approach to Common and not so Common Rashes in the Office FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc 1 Common Rashes Tinea Corporis: Annular- this is not the only criteria Advancing erythematous
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationUpdate in deposition diseases
Genoa, Italy Update in deposition diseases Prof. Franco Rongioletti, Section of Dermatology, Chair of Dermatopathology, University of Genoa,Italy Cutaneous deposition disorders Endogenous Exogenous Cutaneous
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adhesive tape impression 1 Diff Quik in EPD diagnosis, 583 Allergy(ies). See also Food allergy; specific types, e.g., Culicoides hypersensitivity
More informationIntegumentary System
Integumentary System Physiology of Touch Skin: our most sensitive organ Touch: first sense to develop in embryos Most important but most neglected sense How many sensory receptors do we have? (We have
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationClinicopathologic Self-Assessment
Clinicopathologic Self-Assessment Handout Symposium (S003), July 27 th 2017 Maija Kiuru MD PhD Assistant Professor, Departments of Dermatology & Pathology University of California Davis CASE 1: History
More informationS003 CPC Self-Assessment
S003 CPC Self-Assessment Alina G. Bridges, D.O. Associate Professor Program Director, Dermatopathology Fellowship Department of Dermatology, Division of Dermatopathology and Cutaneous Immunopathology Mayo
More informationGoals of this talk. Morbilliform. Common Morphologies in the Hospital 11/7/2017. Hospital Based Dermatology: Common and Tough Consult Cases
Hospital Based Dermatology: Common and Tough Consult Cases Lindy P. Fox MD Associate Professor of Clinical Dermatology Director, Hospital Consultation Service University of California, San Francisco lindy.fox@ucsf.edu
More informationSome skin conditions
Some skin conditions Some skin conditions Acute Inflammatory Dermatoses Chronic Inflammatory Dermatoses Blistering (Bullous) Diseases Panniculitis Disorders of Epidermal Appendages -Urticaria -Acute eczematous
More informationSkin Deep: Cutaneous Lupus. Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016
Skin Deep: Cutaneous Lupus Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016 Introduction: Cutaneous lupus erythematosus LE is an autoimmune disease with a range of clinical manifestations
More informationImmunobullous Diseases: Review and Update. May P. Chan, MD Associate Professor of Pathology and Dermatology University of Michigan
Immunobullous Diseases: Review and Update May P. Chan, MD Associate Professor of Pathology and Dermatology University of Michigan Diagnosis of Immunobullous Diseases Clinical H&E DIF DIAGNOSIS IIF ELISA
More informationU059 Hidradeni-s Suppura-va and Pityriasis Rubra Pilaris: Updates on Treatment
U059 Hidradeni-s Suppura-va and Pityriasis Rubra Pilaris: Updates on Treatment DISCLOSURES I do not have any relevant relationships with industry. Scott Worswick UCLA Dermatology Director of Inpatient
More information